Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
LJN452 - FXR Agonist
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04065841 ELIVATE (CLJN452D12201C)
Non-alcoholic steatohepatitis (NASH)
Phase 2
380
Proportion of patients with resolution of NASH and no worsening of fibrosis OR
improvement in fibrosis by at least one stage without worsening of NASH at Week
48 compared with baseline
Arm A: combination therapytropifexor + licogliflozin
Arm B: tropifexor monotherapytropifexor + licogliflozin placebo
Arm C: licogliflozin monotherapylicogliflozin + tropifexor placebo
Arm D: licogliflozin placebo + tropifexor placebo
Adult patients with biopsy based non-alcoholic steatohepatitis (NASH) and liver
fibrosis
Target Patients
Read-out Milesstone(s)
Publication
2023
2023
80 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation